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Oxidative stressa b s t r a c t
Background and aim: Excessive ethanol consumption can lead to development of hepatic steatosis. Since
the FXR receptor regulates adipose cell function and liver lipid metabolism, the aim of this work was to
examine the effects of the FXR agonist 6ECDCA on alcoholic liver steatosis development and on oxidative
stress induced by ethanol consumption.Methods: Swiss mice (n = 24) received a low-protein diet (6%) and
a liquid diet containing 10% ethanol or water for 6 weeks. In the last 15 days mice received oral treatment
with 6ECDCA (3 mg kg1) or 1% tween (vehicle). The experimental groups (n = 6) were: water + tween,
water + 6ECDCA, ethanol + tween and ethanol + 6ECDCA. Moreover, as a diet control, we used a basal
group (n = 6), fed by a normal-proteic diet (23%) and water. After the treatment period, the animals were
anesthetized for sample collection to perform plasma biochemistry assays, hepatic oxidative stress
assays, hepatic cholesterol and triglycerides measurements, liver histology and hepatic gene expression.
Results: Ethanol associated with low-protein diet induced hepatic oxidative stress, increased plasma
transaminases and induced hepatic lipid accumulation. Many of these parameters were reversed by
the administration of 6ECDCA, including amelioration of lipid accumulation and lipoperoxidation, and
reduction of reactive oxygen species. These effects were possibly mediated by regulation of Srebpf1
and FAS gene expression, both reduced by the FXR agonist. Conclusions: Our data demonstrated that
6ECDCA reverses the accumulation of lipids in the liver and decreases the oxidative stress induced by
ethanol and low-protein diet. This FXR agonist is promising as a potential therapy for alcoholic liver
steatosis.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction and background
Ethanol induces deleterious effects in several systems, including
the gastrointestinal, nervous, cardiovascular, hematological, and
reproductive systems [1]. Among the serious clinical problems
triggered by ethanol abuse, liver diseases are prominent, because
the liver is the primary site of ethanol metabolism and the target
of its own reactive metabolites, particularly acetaldehyde [2]. Lipid
accumulation in hepatocytes, namely steatosis, is the most com-
mon and immediate hepatic manifestation of excessive ethanol
ingestion [3]. While binge drinking typically results in transient
steatosis that resolves if drinking ceases, sustained steatosis due
Fig. 1. Experimental design over 6 weeks. Mice were assigned to either a low (6%) or normal-protein (23%) diet, and a liquid diet (water or 10% ethanol) during 6 weeks. In the
last 15 days, concomitantly, the animals were treated orally with 6ECDCA (3 mg kg1) or vehicle (1% tween 80).
1 AIN-93G 6% Diet Pelleted, Rhoster Industry and Commerce Ltda. São Paulo – SP -
Brazil.
2 Nuvilab CR1, Nuvital Nutrientes S/A. Colombo – PR - Brazil.
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liver damage (i.e., hepatitis) [3]. Lipid peroxidation, a component of
cellular oxidative stress, is responsible, at least in part, by causing
damage to hepatocytes during the process initiated by ethanol.
Lipid homeostasis is altered in general by chronic ethanol
consumption, inducing not only alcoholic hepatic steatosis (AHS)
but also changes in lipids in the blood and other organs [4,5]. Thus,
heavy drinkers may develop serious hepatic problems due to
changes in lipid metabolism, and this may amplify cardiovascular
responses [6].
After decades of research in this ﬁeld, knowledge of the patho-
genesis of the hepatotoxicity of ethanol is still limited [7]. Some
progress has been achieving by establishing the role of oxidative
stress and the inﬂammatory response [7]. It is known that dietary
deﬁciency is a factor predisposing liver diseases in alcoholics. A
low-carbohydrate diet associated with ethanol induces more
severe hepatotoxicity with intense steatosis [8]. Protein deﬁciency
or malnutrition has also reported to cause or contribute to steato-
sis [9,10]. Liver plays a central role in lipid metabolism, and both
dietary deﬁciency and ethanol metabolism perturb metabolic
homeostasis which may be relevant for the pathogenesis of alco-
holic liver disease. However, the mechanisms by which the interac-
tion between ethanol consumption and protein intake deﬁciency
contribute to development of liver injuries are not known.
Inspite of being one of the most public health problems around
the world [11] effective drugs for the treatment of alcoholic liver
diseases are still not available [2]. Although some drugs have been
tested, such as steroids [12] and ursodeoxycholic acid (UDCA) or its
conjugate (TUDCA) [13], studies in patients have not demonstrated
convincing effects [2]. There is increasing interest in the develop-
ment of drugs that modulate the activity of nuclear receptors
involved in the metabolic regulation. The metabolism of lipids in
the liver is regulated by several pathways, which are mediated
by the farnesoid X receptor (FXR), a nuclear receptor highly
expressed in the liver and that function as a transcription factor.
FXR regulates important genes involved in the synthesis and trans-
port of lipoproteins, cholesterol, triglycerides, and bile acids, such
as SHP, SREBP1, Apo-AI and -CII, CYP7a1, and BSEP [14,15]. FXR is
activated by physiological concentrations of bile acids or by potent
agonists, such as 6a-ethyl-chenodeoxycholic acid (6ECDCA) [14].
Due to this critical gene regulation, FXR agonists have been sug-
gested as therapy for cholestasis and liver ﬁbrosis [8] and also as
potential drugs for the treatment of insulin resistance and non-
alcoholic fatty liver disease (NAFLD) [16]. Studies are lacking, how-
ever, on the potential use of FXR agonists on animals with alcoholic
fatty disease, particularly under a condition of low protein diet.Taken all these considerations in account, this work was
planned to evaluate whether the FXR agonist 6ECDCA can prevent
the effects of ethanol in inducing steatosis and oxidative stress in
livers of mice under a condition of low-protein diet.
2. Material and methods
2.1. Animals, diets, and treatments
Swiss male mice (8–10 weeks old), weighting 25–35 g, were
kept at a controlled temperature (22 ± 2 C), under 12 h light–dark
cycle and fed ad libitum. All the protocols were approved by the
institutional ethics committee for animal research (CEEA) and
received the certiﬁcate number 438. Fig. 1 shows the experimental
design and animal groups. Brieﬂy, the animals were separated into
individual cages, and food intake, liquid consumption, and the
body weight of the animals were controlled weekly. During the
six experimental weeks mice received a low-protein diet (chow
with 6% protein1) or normal-protein diet (chow with 23% protein2)
and liquids containing either 10% ethanol or water. In the two last
weeks, the animals were redistributed into 5 groups (n = 6) for the
initiation of oral treatments (gavage) with 6ECDCA (3 mg kg1) or
1% tween 80 (vehicle), once a day for 14 days. Thus, the ﬁnal groups
were: G1 (basal group): normal-protein diet + water + vehicle; G2
(negative control): low-protein diet + water + vehicle; G3: low-
protein diet + water + 6ECDCA; G4 (positive control): low-protein
diet + ethanol + vehicle; and G5: low-protein diet + ethanol +
6ECDCA. The 6ECDCA dose (3 mg kg-1) was based on the experi-
ments performed by Fiorucci et al. (2005) [17].
2.2. Sample collection
At the end of 6th experimental week, the animals were fasted
for 12 h, and then anesthetized with ketamine (80 mg kg1) and
xylazine (10 mg kg1), intraperitoneally. Laparotomy was per-
formed for collection of blood and liver samples. Blood was drawn
from the abdominal cava vein with heparinized syringes, and
plasma was separated by centrifugation (3000 rpm for 10 min)
and stored at 70 C for further analysis. The liver was rapidly col-
lected, frozen in liquid nitrogen and also stored at 70 C. Another
section (major lobe) was appropriately stored for histological
analysis.
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Plasma was used for determination of the enzymatic activity of
aspartate aminotransferase (AST) and alanine aminotransferse
(ALT), as well as to determine cholesterol and triglyceride (TG)
levels. All of the measurements were performed with commercial
kits (Labtest, Lagoa Santa, MG – Brazil) in an automated system
(COBAS 1500).
2.4. Measurement of hepatic cholesterol and triglycerides
Liver samples were subjected to lipid extraction by the gravi-
metric technique according to the proposed by Folch et al. (1957)
[18], with modiﬁcations, using hexane (98.5% pure) as the solvent.
Then, the lipids were resuspended in chloroform and isopropanol
for later determination of cholesterol and triglycerides with com-
mercial kits (Labtest, Lagoa Santa, MG – Brazil) in an automated
system (COBAS 1500).
2.5. Hepatic oxidative stress measurements
To measure the enzyme activities of catalase (Cat), glutathione-
S-transferase (GST), and superoxide dismutase (SOD), which are
indicators of the redox state of hepatocytes, liver samples were
homogenized and centrifuged at 13,000 rpm for 20 min. The
homogenization was performed on ice and with centrifuge at
4 C. The enzymes were analyzed from the supernatant with estab-
lished methods: Cat activity was measured according to Aebi [19],
in spectrophotometric reaction monitored for 60 s at 240 nm; SOD
activity was measured by the ability of this enzyme to inhibit piro-
gallol self-oxidation, in microplate at 440 nm [20]; and the activity
of GST was measured following the method of Habig and
colleagues [21], which is based on the capacity of this enzyme toFig. 2. Relative body weight gain (A), ethanol or water consumption (B), and chow intak
(other four groups). Values represent the percentage of changes in comparison to the 1st
ANOVA and Bonferroni tests. Symbols: ⁄p < 0.05 for the group ethanol + vehicle when co
group when compared with itself since the 1st and 2nd week.conjugate the substrate 2,4-dinitrochlorobenzene (DNCB) with
glutathione in its reduced form, forming a tioether that can be
measured by the increase in absorbance at 340 nm. In addition to
the enzyme activity measurements, the rate of lipid peroxidation
(LPO) was measured by the ferrous oxidation in xylenol orange
(FOX) method following a described protocol [22]. This technique
quantiﬁes the formation of hydroperoxides in lipid phase during
lipid peroxidation (FOX2). GSH levels were measured using the
method described by Sedlak [23] which quantiﬁes the formation
of 5,50-dithiobis-(2-nitrobenzoic acid)-sulﬁdryl groups by a colori-
metric assay. The total reactive oxygen species (ROS) content was
quantiﬁed via the 20-70-dichloroﬂuorescein-diacetate (DCFH-DA)
assay, as proposed by Driver and colleagues [24]. Acetate groups
of DCFH-DA allow it to enter the organelles. These groups are
removed by esterases producing the reduced DCFH within the
organelle, which can be oxidized by peroxides to the ﬂuorescent
oxidized dichloroﬂuorescein (DCF). The formation of DCF was
measured immediately after stopping the reaction on ice with a
spectroﬂuorimeter RF-5301 (Shimadzu), in which the excitation
and emission wavelengths were set at 504 and 529 nm, respec-
tively. A standard curve with oxidized DCF was used to express
the results as nmol mg of protein1. Most of the results were
expressed by the amount of protein in the homogenates, deter-
mined by the Bradford method [25]. This reaction was examined
at 595 nm in a microplate reader, using bovine serum albumin
(BSA) as protein standard [25].
2.6. Liver histology
Cross-sections of the right lobe of the liver were quickly
harvested, stored in buffered 10% formalin for ﬁxation, and stained
with Hematoxylin and Eosin (HE). A further liver sample was
stored in buffered formalin for 3 days and then transferred to ae (C) of mice submitted to a normal-protein diet (basal group) or low-protein diet
week and are expressed as mean ± standard error of the mean, analyzed by two-way
mpared with itself since the 1st and 2nd week, and ⁄⁄p < 0.01 for ethanol + vehicle
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After saturation in sucrose, sections were stored in Tissue-Tek
(O.C.T., Sakura) and rapidly frozen at 80 C, where they
remained until the processing of slides for staining with Sudan
Black and Nile Blue. These histological techniques were used to
conﬁrm the accumulation of lipids in the tissue. The slides were
examined under an optical microscope (LeicaDM2500) to evalu-
ate cellular changes resulting from ethanol treatment or diet.
Scores of steatosis and other lesions, such as inﬂammation, bal-
looning and presence of Mallory’s hyaline bodies, were analyzed
according to the protocol described by Kleiner and colleagues
[26], with slight modiﬁcations. The steatosis grade was based on
parenchymal involvement (%) by lipid drops, in which less than
5% involved was considered grade 0, 5–33% was considered grade
1, 34–66% was grade 2, and more than 66% was considered grade 3.
The ballooning grade was classiﬁed according to the number of
balloon cells: none, grade 0; few balloon cell, grade 1; and predom-
inant balloon cells, grade 2. Also, the steatosis location predomi-
nance (zone 3, zone 1, azonal and panacinar) was considered.2.7. Gene expression
Measurement of the expression of target genes involved in lipo-
genesis and apoptosis was performed for each of the liver samples.
The mRNA levels were determined for the following genes: Srebp1f
[Sterol regulatory element-binding protein 1f], FAS [Fatty acid syn-
thase], CYP7a1 [Cholesterol 7-alpha-monooxygenase], HMGCoA
reductase [3-hydroxy-3-methyl-glutaryl-CoA reductase], ApoB
[Apolipoprotein B], Scd1 [Stearoyl-CoA desaturase], p53 [proteinFig. 3. Plasma concentrations of (A) cholesterol (mg dL1) and (B) triglycerides (mg dL
aminotransferase (ALT) (U L1) in mice fed a low- or normal-protein diet, liquid diet (w
mean ± standard error of the mean, analyzed by one-way ANOVA and Bonferroni tests.53], and Bax [Bcl-2-associated X protein]. The complementary
DNA (cDNA) was synthesized from 2.0 lg of RNA, while following
all of the reaction steps in a speciﬁc program for the PCR-thermo-
cycler. The quality of the synthesized cDNA was evaluated by
quantiﬁcation of the housekeeping gene 36b4, using LightCycler
480 System (Roche). The expression of the above genes was
described subsequently as mRNA relative expression. For this pur-
pose, speciﬁc primers for murine genes were used, and the
sequences (50 ? 30) were prepared by Biolegio Company (Nijme-
gen, The Netherlands).
2.8. Statistical analysis
Data were analyzed for homogeneity of variance and normal
distribution. One-way or two-way ANOVA followed by Bonferroni
post hoc tests were used. The parameters considered in the two-
way ANOVA were time (week) and treatment. The level of signiﬁ-
cance was set at 95% (p < 0.05). Statistical analysis and the prepa-
ration of graphs were performed with Graphpad Prism version
5.0. The results were expressed as mean ± standard error of the
mean.3. Results
3.1. Chow intake, liquid consumption, and body weight of the mice
The group that showed the most expressive body weight gain
was that composed by mice fed a low-protein diet associated with
alcoholic liquid diet (ethanol + vehicle). In comparison, these mice1), and activities of (C) aspartate aminotransferase (AST) (U L1) and (D) alanine
ater or 10% ethanol), and treated with 6ECDCA or vehicle. Values are expressed as
Symbols: ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001.
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protein diet (23%) and water. In addition, we observed a decrease
in ethanol consumption relative to water consumption in both
groups that receive 10% ethanol as the liquid diet (ethanol + vehi-
cle; ethanol + 6ECDCA). However, the treatment with 6ECDCA over
the last 15 days of the experiment did not inﬂuence the liquid or
chow consumption. Fig. 2 shows body weight gain (2A), liquid con-
sumption (2B) and food intake (2C) measured over 6 weeks.3.2. Plasma biochemistry
The agonist 6ECDCA signiﬁcantly decreased cholesterol levels
when compared with the positive and negative control groups,
and maintained plasma level of cholesterol equal to those mice ofFig. 4. Hepatic (A) catalase (lmol min1 mg protein1), (B) superoxide dismutase (U S
glutathione (mg GSH. mg protein1), (E) lipoperoxidation levels (mmol mg protein1) and
diet (water or 10% ethanol), and treated with 6ECDCA (3 mg kg1) or vehicle. Values are
Bonferroni tests. Symbols: ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001.basal group (Fig. 3A). Interestingly, similar results were also
observed for TG. The FXR agonist decreased the plasma TG levels
in the mice independent of the presence of ethanol when compared
with basal group, negative and positive control (Fig. 3B). Regarding
the activity of transaminases (Fig. 3C and D), ethanol increased the
plasma AST and ALT in mice. This increase was in the order of 50%
and 350% for AST and ALT, respectively, when compared with the
negative control (low protein diet + water + vehicle). However,
these elevationswere reversedby administration of the FXR agonist.3.3. Hepatic oxidative stress
Ethanol decreased the activity of catalase (Cat) when compared
with mice that received equal diet and water (Fig. 4A). This effectOD mg protein1), (C) glutathione-S-transferase (lmol mg protein1), (D) reduced
(F) total ROS (mmol mg protein1) in mice fed a low or normal-protein diet, liquid
expressed as mean ± standard error of the mean, analyzed by one-way ANOVA and
Fig. 5. Hepatic (A) lipids (%), (B) triglycerides (mg dL1) and (C) cholesterol
(mg dL1) levels in mice fed a low protein diet, liquid diet (water or 10% ethanol),
and treated with 6ECDCA (3 mg kg1) or vehicle. Values are expressed as
mean ± standard error of the mean, analyzed by one-way ANOVA and Bonferroni
tests. Symbols: ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
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decrease of SOD in the animals fed a low protein diet and ethanol
when compared with basal and negative control groups. The test
drug was able to normalize hepatic SOD to basal activity levels
(Fig. 4B). No signiﬁcant difference was observed in the activity of
hepatic GST among the groups of mice (Fig. 4C). However, the
effect of diet was effectively important for the hepatic level of
reduced glutathione, as the low-protein diet increased GSH levels
in the negative control group (low-protein + water + vehicle),
while the presence of the FXR agonist reduce them, as shown in
Fig. 4D. Ethanol elevated the rate of hepatic lipoperoxidation
(LPO) in 48%. However, the FXR agonist treatment reversed this
effect, and further reduced the LPO (22%) when compared with
negative control (water + vehicle) under the same diet condition
(Fig. 4E). A considerable evaluation of the total quantity of hepatic
ROS (4F) was found in the animals that received ethanol and
vehicle. Corroborating other results, the FXR agonist was also able
to reverse the increased ROS induced by the ethanol.
3.4. Hepatic cholesterol and triglycerides
The lipids accumulated in the liver of mice treated with ethanol
and vehicle expressively increased when compared with the group
of animals treated with water and vehicle. This increase was
potentially reversed by the administration of 6ECDCA in the ani-
mals which received ethanol (Fig. 5A). Similar results were found
for the amount of hepatic triglycerides (5B) and cholesterol (5C).
3.5. Liver histology
Considering the alterations observed in plasma biochemistry,
oxidative stress biomarkers, and the macroscopic aspect of the liver
in mice that received ethanol (yellow dots suggestive of lipid sto-
rages), signiﬁcant histological alterations were expected in the
hepatocytes. Cellular changes were observed mainly in the group
that was treatedwith ethanol. No alterationswere observed inmice
of the basal group, thus the changes described refer speciﬁcally to
the group of animals treated with a low-protein diet. Absence of
steatosis (grade 0) and hepatocyte ballooning code 1, localized
mainly in zone 3, were observed in the negative control (water
and vehicle). The positive control (ethanol and vehicle) mice pre-
sented with micro- and macro-steatosis grade 2 and 3, ballooning
code 0 and 1, and Mallory’s hyaline bodies, both diffuse or predom-
inant in zone 3 (data not shown). In addition, multiple necrotic foci
were observed (data not shown). The FXR agonist 6ECDCA was able
to reverse these alterations, as no changes were observed in histo-
logical sections of mice treated with this drug. The accumulation of
lipids revealed by the HE technique (vacuoles in white) was con-
ﬁrmed by Sudan Black (lipids in black) and Nile Blue (TG in pink)
stains. These histological ﬁndings are shown in Fig. 6.
3.6. Gene expression
Since ethanol consumption induced hepatic steatosis, the
expression of genes that regulate hepatic lipid metabolism was
investigated, as well as genes that participate in apoptosis. The
most signiﬁcant alterations were observed in the expression of
Srebp1f and FAS. Both genes showed the same pattern of expression.
Ethanol induced the expression of Srebp1f and FAS when compared
with basal group, and 6ECDCA markedly decreased the expression
of both genes, even in animals that did not receive ethanol. These
data are shown in Fig. 7, normalized by the housekeeping gene
36b4. In addition, the relative expression of other genes linked to
lipid metabolism was evaluated: the enzymes Cyp7a1, Scd1,
HMGCoA reductase, and the lipoprotein ApoB. However, no
signiﬁcant alteration was observed in these genes, regardless ofethanol or FXR agonist treatment. Absence of signiﬁcance was also
found for expression of the apoptosis-linked genes Bax and p53.
These data are shown in the Supplementary material (Table S1).4. Discussion
The inﬂuence of a low-protein diet in aggravating the hepatic
injuries induced by ethanol is very clear in the data of the present
work. Ethanol induced the prominent biochemical and genetic
alterations when it was consumed together with 6% protein chow.
The combination of ethanol + low-protein diet increased the
hepatic accumulation of triglycerides, plasma ALT and AST activity,
and the hepatic levels of LPO and ROS, also decreased Cat and SOD
Fig. 6. Hepatic histology of mice fed a low-protein diet, showing cellular changes, particularly fatty vacuoles (arrows), indicating steatosis. (A) Water + vehicle, (B)
water + 6ECDCA (3 mg kg1), (C) ethanol + vehicle, and (D) ethanol + 6ECDCA (3 mg kg1). Staining: Hematoxylin and Eosin, Sudan Black, and Nile Blue.
Fig. 7. mRNA expression of hepatic (A) Srebp1f and (B) Fatty acid synthase (FAS) of mice fed a low or normal-protein diet, liquid diet (water or 10% ethanol), and treated with
the FXR agonist 6ECDCA (3 mg kg1) or vehicle. Values are expressed as mean ± standard error of the mean, normalized by the gene 36b4. One-way ANOVA and Bonferroni
test were used for statistical analysis. Symbols: ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
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Our data are similar to other studies recently conducted on non-
alcoholic steatosis, in which protein malnutrition induced hepatic
steatosis [27].The drug tested in this study, 6ECDCA, reversed the increase in
both transaminases that was induced by ethanol, and decreased
the plasma levels of TG and cholesterol. Moreover, the FXR agonist
was effective in normalizing biomarkers of oxidative stress, such as
26 F.A.R. Lívero et al. / Chemico-Biological Interactions 217 (2014) 19–27the activity of liver Cat and SOD and the rate of lipid peroxidation
and total ROS. The data showed that LPO was 2-fold higher in eth-
anol consuming mice, but treatment with 6ECDCA signiﬁcantly
reduced this LPO elevation, thus indirectly reducing damage to
hepatocytes. This mechanism may be responsible, at least in part,
for the reduction in both plasma transaminases (ALT and AST) in
mice treated with the FXR agonist. Transaminases release can be
caused by cell lysis or increases in plasma membrane permeability,
and both phenomena are induced by lipid peroxidation. It was pre-
viously reported that the absence of hepatic FXR (FXR-null mice)
spontaneously generates oxidative stress [28], so it was expected
that an FXR agonist would reduce oxidative stress, as we observed
in 6ECDCA-treated animals.
The production of ROS is a naturally occurring process, and a
variety of enzymatic and non-enzymatic mechanisms are involved
in cellular protection against ROS [29]. Importantly, some of these
mechanisms are broken after long periods of exposure to ethanol.
In this research we found an increase in the overall amount of ROS
induced by the association of ethanol and low-protein diet. Fur-
thermore, chronic ethanol ingestion causes an up-regulation of
mitochondrial manganese superoxide dismutase (Mn-SOD) at the
mRNA level, which seems to be a protective mechanism [30]. With
repeated ethanol administration the increased level of Mn-SOD is
gradually diminished. Thus, the adaptive response of Mn-SOD is
blunted, leading to increased toxicity with prolonged ethanol
exposure [31]. In agreement, our results indicate a reduction in
the hepatic activity of SOD in animals that received only ethanol
and vehicle when compared with the basal and negative control
groups. In the group fed the same diet and ethanol, but treated
with 6ECDCA, SOD activity returned to basal levels. Catalase is
another important antioxidant and cytoprotective enzyme in hepa-
tocytes that are exposed to ethanol [32]. Cat activity was decreased
in the group of mice that received ethanol, compared with the neg-
ative control group. However, this effect was reversed by the
administration of 6ECDCA. We believe that the present work is
the ﬁrst to report the inﬂuence of this FXR agonist in hepatic Cat
and SOD activities. These data suggest the recognition of 6ECDCA
as an antioxidant drug.
Ethanol has been shown to diminish the levels of GSH, partic-
ularly in the mitochondria, which usually require high levels of
GSH to eliminate ROS generated during mitochondrial respiratory
chain activity [33]. Nevertheless, the effects of ethanol on the lev-
els of GSH are controversial comparing published data. Hassing
and colleagues [34] found an increase in GSH levels in rats fed
with ethanol, while other authors reported decreases in GSH lev-
els after ethanol intake for prolonged periods and reported no
change in hepatic GSH levels after 7 weeks of ethanol consump-
tion [35]. In our data an increase in GSH concentration was found
only in the negative control group, possibly indicating a diet-
linked effect, independent of ethanol or 6ECDCA treatment. From
the data presented, the exact mechanism for this effect cannot be
inferred. GSH is an essential component of the antioxidant system
and acts as a substrate for GST, which is important in the protec-
tion against oxidative stress [33,36]. The enzyme GST did not
present signiﬁcant differences of activity among the groups of
mice, even in those treated with FXR agonist. However, down-
regulation of GST expression was previously reported in FXR-null
mice [28].
Steatosis due to chronic ethanol abuse is largely attributed to
two main causes. First, as mentioned above, ethanol metabolism
leads to oxidative stress, which results in cellular damage and lipid
peroxidation. Second, lipid synthesis is induced by the activation of
the sterol response element binding proteins (SREBPs) [37–39].
Activation of FXR down-regulates SREBPs, which inhibits the syn-
thesis and promotes the degradation of TG, and fatty acid oxidation
[39]. In our study, the relative gene expression of Srebp1f wasdecreased with administration of the FXR agonist 6ECDCA, which
also reduced the accumulation of lipids in the liver. The SREBP1
protein regulates genes involved in the synthesis of TG, such as
FAS, which catalyzes the ﬁnal step in the biosynthesis of fatty
acids. Thus, the presented results of gene expression are comple-
mentary with previous data, since 6ECDCA reduced the expression
of the genes of both the factor SREBP1 and the enzyme FAS. This
suppressed gene expression may have affected the hepatic lipids
accumulation induced by the ethanol, corroborating the data of
Yang and colleagues [40].
It should be mentioned that although the administration of
alcohol in drinking-water is not considered the best model to study
alcoholic liver disease, this consumption over several weeks mim-
ics human behavior patterns of intermittent alcohol use and
changes in dietary intake [41]. The intake of ethanol for prolonged
periods has demonstrated to also affect lipid metabolism in extra-
hepatic tissues, leading to the development of hypertriglyceride-
mia and hypercholesterolemia [4,42]. Interestingly, in agreement
with previously reported studies using the FXR agonist GW4064
[43] and WAY-362450 [44], 6ECDCA was able to decrease plasma
and hepatic levels of cholesterol and TG in mice that received eth-
anol. The decreased levels of circulating lipids and of accumulation
of hepatic triglycerides and cholesterol are also reﬂected in the lip-
ids observed by liver histology, mainly in samples stained with
Sudan Black (speciﬁc for lipids evidence) and Nile Blue (speciﬁc
for TG evidence) techniques. Additionally, ethanol consumption
increased the body weight of animals. The increase in body weight
gain was not concomitant with an increment in food intake, which
conﬁrms that body weight gain was due to the intake of ethanol, an
important caloric source, and not the result of diet. However, body
weight gain was not observed in mice that received a combination
of ethanol + 6ECDCA.
The whole of the results allow concluding that ethanol is able to
induce hepatic oxidative stress and the accumulation of lipids in
the livers of mice under a condition of low protein-diet. This dam-
age is reversed by the oral administration of 3 mg kg1 6ECDCA, an
FXR agonist. Importantly, 6ECDCA administration is effective in
ameliorating hepatic lesions and metabolism disturbances induced
by ethanol, and it also protects hepatocytes from oxidative stress.
These data corroborate those recently published with another
FXR agonist, namely WAY-362450 [44]. The FXR agonist 6ECDCA
is also promising as a potential therapy for alcoholic liver steatosis.
Further studies are necessary to validate these results, including
long-term 6ECDCA treatment and a toxicity investigation.Transparency Document
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